Stock Message Boards
ETF Channel
Market News Video Self Directed Investor The Warren Buffetts Next Door Stock message boards Portfolio Channel
VVUS Description — Vivus, Inc.

VIVUS is a biopharmaceutical company. Co.'s drug Qsymia (phentermine and topiramate extended-release) is an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Co.'s drug STENDRA, or avanafil, is an oral phosphodiesterase type 5, inhibitor that Co. has licensed from Mitsubishi Tanabe Pharma Corporation, for the treatment of erectile dysfunction.

Company Name:  Vivus, Inc.
Website:  www.vivus.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding VVUS:  21
Total Market Value Held by ETFs:  $30,447,539
Total Market Capitalization:  $329,000,000
% of Market Cap. Held by ETFs:  9.25%
 ETF   VVUS Weight   VVUS Amount 
 XPH   1.09%   $12,122,708         
 IHE   0.55%   $4,709,184         
 IWM   0.02%   $4,642,518         
 IBB   0.07%   $4,312,193         
 IWO   0.03%   $2,108,287         
 VBK   0.02%   $864,784         
 IWC   0.08%   $726,502         
 VHT   0.01%   $431,967         
 BIB   0.04%   $215,194         
 PRFZ   0.01%   $101,397         
List of all 21 ETFs holding VVUS »
10 ETFs With Stocks That Insiders Are Buying
25 Dividend Giants Widely Held By ETFs
25 S.A.F.E. Dividend Stocks Increasing Payments For Decades
Broker Darlings: Top 15 Analyst Picks of the Dow
Top 25 Broker Analyst Picks of the S&P 500
Forgotten S&P 500 Giants: Analysts' Current Least Favorites
25 Top Ranked Socially Responsible Dividend Stocks
10 Oversold ETFs
The Top 10 DividendRank'ed Stocks
The DividendRank Top 25
The Top 10 DividendRank'ed DJIA Components
The Top 10 DividendRank'ed Dow Transports Components
The Top 10 DividendRank'ed Dow Utilities Components
The Top 10 DividendRank'ed Nasdaq 100 Components
10 Stocks Going Ex-Dividend
10 Oversold Dividend Stocks
10 Stocks Where Yields Got More Juicy
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Top Ranked Dividend Stocks With Insider Buying
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Metals Stocks You Can Buy Cheaper Than Insiders Did
10 Oversold Metals Stocks
10 Must-Know High-Yield REITs
10 Top DividendRank'ed Financials
10 Top DividendRank'ed Metals Stocks
10 Oversold Energy Stocks
10 Top DividendRank'ed Energy Stocks
10 Top DividendRank'ed Utility Stocks
10 Stocks Crossing Below Book Value
10 Stocks Crossing Above Their 200 Day Moving Average
10 Stocks Crossing Below Their 200 Day Moving Average
10 ETFs Crossing Above Their 200 DMA
The 10 Biggest ETFs
The 10 Best ETF Performers
The 10 Worst ETF Performers
10 ETFs With Notable Inflows
10 ETFs With Notable Outflows
The Top 10 DividendRank'ed Canadian Stocks
The DividendRank Canada Top 25
10 Canadian Stocks Going Ex-Dividend
10 Oversold Canadian Stocks
10 Canadian Stocks Where Yields Got More Juicy
10 Must-Know High-Yield Canadian Real Estate Stocks
10 Top DividendRank'ed Canadian Financials
10 Must-Know High-Yield Canadian Energy Stocks
10 Canadian Stocks Crossing Below Book Value
10 Canadian Stocks Crossing Above Their 200 Day Moving Avg
10 Canadian Stocks Crossing Below Their 200 Day Moving Avg
Stock market game
Quotes delayed 20 minutes

Sell (1.00 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite


PARTNER NEWS:

Wed, Nov 19, 8:07 AM, Zacks
Why VIVUS (VVUS) Might Be a Diamond in the Rough - Tale of the Tape
VIVUS is well-equipped to bounce down the road with solid estimate revisions and an impressive Zacks Rank and looks well positioned for a solid gain

Tue, Nov 11, 10:20 AM, Zacks
Orexigen Turns Around with Q3 Earnings Beat, Shares Soar - Analyst Blog
Orexigen (OREX) swung to profit in the third quarter of 2014 with earnings of 9 cents per share beating the Zacks Consensus Estimate of 5 cents.

ETFs Holding VVUS | Vivus, Inc. | ETF Channel | www.ETFChannel.com | Copyright © 2009 - 2014, All Rights Reserved

Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.